NCT03071445

Brief Summary

Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle . The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk . Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain. Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential. ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction. The MID-C System inherent benefits are:

  • Only two screws are used
  • Incision size is much smaller
  • Simpler operation with shorter operative time
  • Less complications (attributed to the three points above).
  • Minimal spinal mobility loss. All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure). The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years. This study is designed to demonstrate that the MID-C System is safe and effective.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2012

Longer than P75 for all trials

Geographic Reach
2 countries

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

February 26, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 7, 2017

Completed
Last Updated

March 7, 2017

Status Verified

February 1, 2017

Enrollment Period

4 years

First QC Date

February 26, 2017

Last Update Submit

March 1, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • No Device related Serious Adverse Event

    2 years

  • No significant curve progression above or below the implant

    6 months, 1 year, 2 years

Secondary Outcomes (2)

  • Minimum of 50% deformity correction within 6 months

    6 months

  • Evaluate the correction period using X-ray

    2 years

Eligibility Criteria

Age11 Years - 20 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The study is designed as a prospective, non randomized, open label study with a 24-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system will be included during a 1-years enrollment period.

You may qualify if:

  • Adolescence above and inclusive 11 years old
  • Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5
  • Completed at least 6 months of conservative therapy (e.g., P.T., bracing, traction, or others).
  • Reisser sign of 2 to 4
  • Appropriate candidate for posterior surgical approach
  • Subject has Good general health.
  • Subject has no hypersensitivity and allergies to Titanium
  • Subject guardians willing to sign a written informed consent form (ICF).surgeon

You may not qualify if:

  • Cobb angle over 55 degrees
  • Other non idiopathic scoliosis.
  • AIS which is not defined as Lenke type 1 or 5
  • Previous spine surgery.
  • Allergy to any component of the device.
  • Active systemic disease, such as AIDS, HIV, or active infection
  • Back or leg pain of unknown etiology
  • Systemic disease that would affect the subject's welfare or overall outcome of the study.
  • Mentally compromised

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

University of Pecs

Pécs, H-7632, Hungary

Location

Spitalul de Copii Sf. Maria

Iași, Romania, Romania

Location

Maria Sklodowska Curie

Bucharest, Romania

Location

Study Officials

  • Sergiu Straticiuc-ciongradi, MD

    Spitalul de Copii Sf. Maria Lasi

    PRINCIPAL INVESTIGATOR
  • Peter Than, MD

    University of Pecs Medical School Hungary

    PRINCIPAL INVESTIGATOR
  • Gheorghe Burnei, MD, PhD

    Maria Sklodowska Curie, Bucharest

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 26, 2017

First Posted

March 7, 2017

Study Start

April 1, 2012

Primary Completion

April 1, 2016

Study Completion

April 1, 2016

Last Updated

March 7, 2017

Record last verified: 2017-02

Data Sharing

IPD Sharing
Will not share

Locations